Increasing O-GlcNAcylation levels by the OGA inhibitor, NButGTA, was shown to reduce Aβ40, Aβ42 peptides levels and plaque formation, resulting in cognition improvement in the 5xFAD mouse model of Alzheimer’s disease [70]. This evidence concerns the gene OGA and early-onset autosomal dominant Alzheimer disease.